

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
14 August 2025 (14.08.2025)



(10) International Publication Number
WO 2025/170991 A1

(51) International Patent Classification:
C12N 5/0783 (2010.01) A61K 40/11 (2025.01)

(21) International Application Number:
PCT/US2025/014572

(22) International Filing Date:
05 February 2025 (05.02.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/551,459 08 February 2024 (08.02.2024) US

(71) Applicant: KITE PHARMA, INC. [US/US]; 2400 Broadway, Santa Monica, California 90404 (US).

(72) Inventors: BERENT-MAOZ, Beata; Kite Pharma, Inc., c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). LIU, Yijun; Kite Pharma, Inc., c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US).

(74) Agent: LOPEZ, Miguel A. et al.; Kite Pharma, Inc., c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

(54) Title: METHODS FOR GENERATING ENGINEERED LYMPHOCYTES WITH ENRICHED T MEMORY STEM CELLS




FIG. 1

(57) Abstract: Provided herein are methods for manufacturing CAR-T cell products with high purity of TSCM subsets (>90%), independent of the variations from incoming leukapheresis. In some embodiments, to isolate the CCR7 and CD45RA double positive T cell subset, the processes described herein deplete CD45RO positive cells from leukapheresis and positively enrich for a CD4 and CD8 T cell population to isolation both TSCM and effector memory T cell (TEMRA) subsets, both of which positively express CD45RA and CCR7.

[Continued on next page]

LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*